AYTU - Company ID 0001385818
AYTU BIOPHARMA, INC (AYTU) reported net income of -$14.30M for fiscal year 2026, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2026 | -$14.30M | -5.4% |
| FY 2025 | -$13.56M | +14.4% |
| FY 2024 | -$15.84M | +7.1% |
| FY 2023 | -$17.05M | +84.3% |
| FY 2022 | -$108.78M | -86.6% |
| FY 2021 | -$58.29M | -327.9% |
| FY 2020 | -$13.62M | +49.8% |
| FY 2019 | -$27.13M | -166.3% |
| FY 2018 |
AYTU BIOPHARMA, INC (AYTU) reported net income of -$14.30M for fiscal year 2026, as filed in its audited annual report with the SEC.
Between fiscal 2012 and fiscal 2026, AYTU BIOPHARMA, INC's net income declined from -$59.67K to -$14.30M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$10.19M |
| +54.7% |
| FY 2017 | -$22.51M | +20.1% |
| FY 2016 | -$28.18M | -264.9% |
| FY 2015 | -$7.72M | -12413.0% |
| FY 2014 | -$61.72K | -7.7% |
| FY 2013 | -$57.32K | +3.9% |
| FY 2012 | -$59.67K | - |